GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the start of a pivotal phase III study, LATITUDE-TIMI 60, to evaluate the effects of losmapimod in patients presenting with acute coronary syndrome.
Source: GSK news - Category: Pharmaceuticals Source Type: news